Cited By
View all- Liu S(2024)Self-assembled lipid-based nanoparticles for chemotherapy against breast cancerFrontiers in Bioengineering and Biotechnology10.3389/fbioe.2024.148263712Online publication date: 29-Oct-2024
Combined Effects of PC002 and Anticancer Drugs in Ewing's Sarcoma Cells
Author: 
Zhirui NingAuthors Info & Claims
Pages 420 - 424
Abstract
Ewing's Sarcoma is a rare malignant tumor that grows in bones or nearby soft tissues. Current treatment focuses on chemotherapy, radiation therapy, and surgery, yet chemoresistance is common and remains the leading cause of treatment failure. PC002 is recently found effective in treating Ewing's Sarcoma in vitro and in vivo. However, the mechanism of action of PC002 is still under dispute, and no experiments have been conducted to explore its combination therapy in Ewing's Sarcoma cells. Thus, this study was performed to elucidate the mechanism of action of PC002 and facilitates the selection of future combination therapies for Ewing's Sarcoma. Vincristine, ABT-199, ABT-263, and Olaparib were combined with PC002. High-throughput screening and Fluorescence-activated Cell Sorting tests were performed in the A673 Ewing cell line to examine the drugs’ effects on inhibiting cell proliferation and inducing apoptosis. The results suggest that there was no antagonism between PC002 and these drugs. We discovered that the combination of PC002 and ABT-263 is highly synergistic (p<0.001), which should be further explored as a promising combination drug. The combinations of PC002 with Vincristine and with Olaparib are also potential therapeutic tools in combating chemoresistance and increasing the efficacy of the drugs in Ewing's Sarcoma.
References
[1]
Seren Durer, & Shaikh, H. 2022, March 7. Ewing Sarcoma. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK559183/
[2]
Sencen, L. 2019. Ewing Sarcoma - NORD (National Organization for Rare Disorders). NORD (National Organization for Rare Disorders); NORD. https://rarediseases.org/rare-diseases/ewing-sarcoma/#:∼:text=The%20annual%20incidence%20of%20Ewing,(more%20than%20five%20years).More references
[3]
Elzi, D. J., Song, M., Houghton, P. J., Chen, Y., & Shiio, Y. 2015. The role of FLI-1-EWS, a fusion gene reciprocal to EWS-FLI-1, in Ewing sarcoma. Genes & Cancer, 6(11-12), 452–461. https://doi.org/10.18632/genesandcancer.86
[4]
Oxford. 2013, August 8. Figure 2. (A) RT-QPCR for a panel of EWS-FLI1-modulated genes along... ResearchGate; ResearchGate. https://www.researchgate.net/figure/A-RT-QPCR-for-a-panel-of-EWS-FLI1-modulated-genes-along-time-series-experiments-in_fig6_255736076
[5]
Guo, D. 2021, December. PC002 for Ewing's Sarcoma.
[6]
Palumbo, R., Palmeri, S., Gatti, C., Villani, G., Cesca, A., & Toma, S. 1998. Combination chemotherapy using vincristine, adriamycin, cyclophosphamide (VAC) alternating with ifosfamide and etoposide (IE) for advanced soft tissue sarcomas: a phase II study. Oncology Reports. https://doi.org/10.3892/or.5.1.69
[7]
Ordóñez, J. L., Amaral, A. T., Carcaboso, A. M., Herrero-Martín, D., García-Macías, M. del C., Sevillano, V., Alonso, D., Pascual-Pasto, G., San-Segundo, L., Vila-Ubach, M., Rodrigues, T., Fraile, S., Teodosio, C., Mayo-Iscar, A., Aracil, M., Galmarini, C. M., Tirado, O. M., Mora, J., & de Álava, E. 2015. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin. Oncotarget, 6 (22), 18875–18890. https://doi.org/10.18632/oncotarget.4303
[8]
Van Mater, D., & Wagner, L. 2019. Management of recurrent Ewing sarcoma: challenges and approaches. OncoTargets and Therapy, Volume 12, 2279–2288. https://doi.org/10.2147/ott.s170585
[9]
Ewing Sarcoma - Childhood and Adolescence - Statistics. 2012, June 26. Cancer.net. https://www.cancer.net/cancer-types/ewing-sarcoma-childhood-and-adolescence/statistics#:∼:text=The%20overall%205%2Dyear%20survival%20rate%20for%20people%20withMurfin, K. (2021, May 28). How is Ewing's sarcoma treated? MD Anderson Cancer Center; MD Anderson Cancer Center. https://www.mdanderson.org/cancerwise/progress-in-ewings-sarcoma-treatment.h00-159460845.html#:∼:text=Only%20about%2030%25%20of%20patients,for%20patients%20with%20relapsed%20disease.
[10]
Murfin, K. 2021, May 28. How is Ewing's sarcoma treated? MD Anderson Cancer Center; MD Anderson Cancer Center. https://www.mdanderson.org/cancerwise/progress-in-ewings-sarcoma-treatment.h00-159460845.html#:∼:text=Only%20about%2030%25%20of%20patients,for%20patients%20with%20relapsed%20disease.
[11]
Below, J., & Das, J. M. 2022, July 11. Vincristine. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK537122/#:∼:text=Vincristine%20belongs%20to%20a%20group,by%20interfering%20with%20microtubule%20polymerization.
[12]
Dlugosz, P. J., Billen, L. P., Annis, M. G., Zhu, W., Zhang, Z., Lin, J., Leber, B., & Andrews, D. W. 2006. Bcl-2 changes conformation to inhibit Bax oligomerization. The May, W. A., Grigoryan, R. S., Keshelava, N., Cabral, D. J., Christensen, L. L., Jenabi, J., Ji, L., Triche, T. J., Lawlor, E. R., & Reynolds, C. P. 2013. Characterization and Drug Resistance Patterns of Ewing's Sarcoma Family Tumor Cell Lines. PLoS ONE, 8 (12), e80060. https://doi.org/10.1371/journal.pone.0080060
[13]
Goulooze, S. C., Cohen, A. F., & Rissmann, R. 2015. Olaparib. British Journal of Clinical Pharmacology, 81 (1), 171–173. https://doi.org/10.1111/bcp.12761
[14]
May, W. A., Grigoryan, R. S., Keshelava, N., Cabral, D. J., Christensen, L. L., Jenabi, J., Ji, L., Triche, T. J., Lawlor, E. R., & Reynolds, C. P. 2013. Characterization and Drug Resistance Patterns of Ewing's Sarcoma Family Tumor Cell Lines. PLoS ONE, 8 (12), e80060. https://doi.org/10.1371/journal.pone.0080060
[15]
Tsafou, K., Katschnig, A. M., Radic-Sarikas, B., Mutz, C. N., Iljin, K., Schwentner, R., Kauer, M. O., Mühlbacher, K., Aryee, D. N. T., Westergaard, D., Haapa-Paananen, S., Fey, V., Superti-Furga, G., Toretsky, J., Brunak, S., & Kovar, H. 2018. Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers. Oncotarget, 9 (57), 31018–31031. https://doi.org/10.18632/oncotarget.25760
[16]
Mohamad Anuar, N. N., Nor Hisam, N. S., Liew, S. L., & Ugusman, A. 2020. Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent. Frontiers in Pharmacology, 11. https://doi.org/10.3389/fphar.2020.564108
[17]
Gorthi, A., Romero, J. C., Loranc, E., Cao, L., Lawrence, L. A., Goodale, E., Iniguez, A. B., Bernard, X., Masamsetti, V. P., Roston, S., Lawlor, E. R., Toretsky, J. A., Stegmaier, K., Lessnick, S. L., Chen, Y., & Bishop, A. J. R. 2018. EWS–FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. Nature, 555 (7696), 387–391. https://doi.org/10.1038/nature25748
Index Terms
- Combined Effects of PC002 and Anticancer Drugs in Ewing's Sarcoma Cells
Index terms have been assigned to the content through auto-classification.
Recommendations
Insilico Docking Studies on Anticancer Drugs for Breast Cancer
IACSIT-SC '09: Proceedings of the 2009 International Association of Computer Science and Information Technology - Spring ConferenceCancer can be described as the uncontrolled growth of abnormal cells. Breast cancer is the second most common type of cancer after lung cancer. Normal breast cells and most breast cancer cells have receptors that attach to circulating estrogen and ...
Comments
Please enable JavaScript to view thecomments powered by Disqus.Information & Contributors
Information
Published In
October 2022
594 pages
ISBN:9781450398442
DOI:10.1145/3570773
Copyright © 2022 ACM.
Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than ACM must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from [email protected]
Publisher
Association for Computing Machinery
New York, NY, United States
Publication History
Published: 09 December 2022
Check for updates
Author Tags
Qualifiers
- Research-article
- Research
- Refereed limited
Conference
ISAIMS 2022
ISAIMS 2022: 2022 3rd International Symposium on Artificial Intelligence for Medicine Sciences
October 13 - 15, 2022
Amsterdam, Netherlands
Acceptance Rates
Overall Acceptance Rate 53 of 112 submissions, 47%
Contributors
Other Metrics
Bibliometrics & Citations
Bibliometrics
Article Metrics
- View Citations1Total Citations
- 19Total Downloads
- Downloads (Last 12 months)6
- Downloads (Last 6 weeks)1
Reflects downloads up to 16 Dec 2024
Other Metrics
Citations
Cited By
View all- Liu S(2024)Self-assembled lipid-based nanoparticles for chemotherapy against breast cancerFrontiers in Bioengineering and Biotechnology10.3389/fbioe.2024.148263712Online publication date: 29-Oct-2024
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Sign inFull Access
View options
View or Download as a PDF file.
PDFeReader
View online with eReader.
eReaderHTML Format
View this article in HTML Format.
HTML Format